44 Wealth Management’s AbbVie ABBV Stock Holding History

44 Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$445K	Buy	1,769 +444	+34%	+$95.5K	0.15%	144
2026 Q1	$288K	Sell	1,325 -6	-0.5%	-$1.33K	0.1%	163
2025 Q4	$304K	Buy	+1,331	New	+$303K	0.1%	172
2025 Q3	–	Sell	-1,787	Closed	-$332K	–	201
2025 Q2	$332K	Sell	1,787 -1,028	-37%	-$191K	0.12%	165
2025 Q1	$590K	Sell	2,815 -230	-8%	-$44.7K	0.22%	123
2024 Q4	$541K	Sell	3,045 -58	-2%	-$10.7K	0.21%	126
2024 Q3	$583K	Buy	+3,103	New	+$579K	0.21%	127
2023 Q2	$244K	Sell	1,810 -19	-1%	-$2.79K	0.08%	152
2023 Q1	$291K	Sell	1,829 -83	-4%	-$12.7K	0.1%	146
2022 Q4	$309K	Sell	1,912 -83	-4%	-$12.7K	0.11%	141
2022 Q3	$268K	Buy	1,995 +33	+2%	+$4.74K	0.11%	142
2022 Q2	$300K	Buy	+1,962	New	+$300K	0.12%	137
2021 Q1	–	Sell	-4,075	Closed	-$437K	–	156
2020 Q4	$437K	Buy	+4,075	New	+$392K	0.2%	105

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

44 Wealth Management's ABBV Position: Q2 2026 in Review

44 Wealth Management increased its AbbVie (ABBV) stake by 34% in Q2 2026, buying an estimated $95.5K and bringing the position to 1,769 shares worth $445K. The position accounts for 0.15% of the portfolio, ranked #144.

44 Wealth Management first reported a position in ABBV in Q4 2020 and has held it in 13 quarters since. The position peaked at $590K in Q1 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

44 Wealth Management held 1,769 shares of AbbVie worth $445K as of Q2 2026.
44 Wealth Management bought 444 AbbVie shares in Q2 2026, an estimated $95.5K.
AbbVie made up 0.15% of 44 Wealth Management's portfolio in Q2 2026, its #144 holding.
44 Wealth Management first reported a position in AbbVie in Q4 2020 and has held it in 13 quarters since.
44 Wealth Management's AbbVie position peaked at $590K in Q1 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 44 Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.